CClinicalTrials.gg
CompletedNCT05078385Updated Nov 20, 2024

Safety of Extracellular Vesicles for Burn Wounds

A Phase 1 interventional study of AGLE-102 in Burns, sponsored by Aegle Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Aegle Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Treatment of patients with deep second degree burns of the skin with extracellular vesicles (EV) isolated from bone marrow derived mesenchymal stem cells.

Read the detailed description

This study is designed to examine the safety and efficacy, in 10 patients of administration of allogeneic MSC EV to deep second degree burn wounds. The dose level delivered will be approximately 1 X 107 EV particles for each cm2 treated area. Wounds eligible for treatment will not exceed 600 cm2 per wound or collection of wounds in a defined anatomical area (e.g., arm, leg, chest) treated. Patients with 20% or greater TBSA in total (3700 cm2 in a 70 kg, 175 cm subject) will be ineligible to participate in the study. The first treatment will be administered within 48 hours of the burn injury. Two additional administrations of EV will be given approximately one week (day 5-7 post-injury) and two weeks after the first treatment (unless the wound is fully closed, in which case the patient will continue to be monitored at weekly intervals through 5 weeks, then at 8, 12, 26, and 54 weeks). Safety will be assessed by collection of adverse event data. The potential for wound healing efficacy will be evaluated by recording the percent of burns re-epithelialized within 8 weeks as well as the time to complete closure. Wound closure will be defined as complete re-epithelialization that is not subject to re-injury during dressing changes or as a result of normal daily activities (e.g., wearing clothing, eating, sleeping). The potential for tissue regeneration and restoration of pigmentation, hair growth and skin texture will be evaluated by scoring healing and scar formation using POSAS. Assessment of the potential for prevention of conversion will be done using LDI. Deep second degree wounds presenting at screening that are assessed to be deeper by LDI at the 5-7 day reading than at the initial evaluation in the first 72 hours will be considered to have undergone conversion. Exploratory endpoints will include monitoring for the presence of an immunologic response in recipients.

02

Conditions studied

  • Burns

Browse trials for

03

In context

Burns

719 studies on the registry are indexed under Burns; 145 are open to participants now.

This study's enrollment of 1 is below the median of 40 across 524 interventional studies indexed under Burns.

Browse Burns studies →

Lead sponsor

Aegle Therapeutics is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Eighteen years of age or older with deep second degree thermal burn wounds
  2. Index burn injury within the prior 72 hours
  3. Subjects must understand and be willing and able to give written informed consent
  4. Subjects must agree to have blood draws performed per protocol
  5. Subjects must be accessible for wound treatment and assessment visits
  6. Males and females must agree to use an acceptable method of contraception. Exceptions will be females of non-childbearing age and monogamous males who are partners of females of non-childbearing age. Acceptable methods of birth control include; history of sterilization, oral contraceptives, depo-progesterone injections, a barrier contraceptive such as a condom with or without spermicide cream or gel, diaphragms or cervical cap with or without spermicide cream or gel, or an intrauterine device (IUD).
  7. Maximum index wound size at screening limited to single or multiple wounds (in a defined anatomical area) cumulatively ≤ 600 cm2. Minimum wound size at screening: 30 cm2. Other wounds may be present that are treated separately from this protocol subject to the maximum TBSA exclusion criteria listed below.

Exclusion criteria

Exclusion Criteria:

  1. Solely first degree or solely third degree burns
  2. Cumulative burn area ≥ 20% TBSA (20% TBSA corresponds to 3700 cm2 in a 70 kg, 175 cm subject)
  3. Burns that occur over a previous scar
  4. Chemical, radiation, or electrical burns
  5. Subjects with superficial second degree burn who are expected to heal within 2 weeks with standard therapy
  6. Evidence of active infection at the wound site
  7. Evidence of significant wound healing prior to treatment
  8. Burn wounds requiring surgery (other than debridement), or skin grafting
  9. Wound exclusively located in the area of fingers, toes, face, or perineum
  10. Wound that extends > 50% across one or more joints
  11. Have any requirement for the use of systemic steroids or immunosuppressive medications
  12. Subjects allergic to human albumin, streptomycin, or penicillin
  13. Be a pregnant female or nursing mother
  14. Subjects who are known or found to be HIV positive
  15. History of alcohol or substance abuse requiring treatment within the past 12 months.
  16. Severe medical conditions

    1. Malignancy (other than non-melanoma skin cancer) not in remission or in remission less than 5 years
    2. Life expectancy less than two years
    3. Severe cardiopulmonary disease restricting ambulation to the clinical facility
  17. WBC \<3 or > 20 x109/L, Hgb \< 9g/dL, platelet count 100x109/L or less, serum creatinine > 1.5 times the upper normal limit, AST or ALT > 2.4 times upper normal limit
  18. Known history of coagulopathy
  19. Subjects who have a reasonable likelihood of being a recipient of tissue or organ transplantation
  20. History of poor compliance, unreliability
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    AGLE-102

    AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)

    Drug: AGLE-102

Interventions

  • DrugAGLE-102

    AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)

06

What researchers measure

Primary outcomes

  1. Examine the safety of applying up to three applications of EVs to deep 2nd degree burn wounds up to 600 cm2

    Examine the safety of applying up to three applications of EVs to deep 2nd degree burn wounds up to 600 cm2 by evaluating the number of participants with treatment-related adverse events as assessed cy CTCAE v4.0

    Time frame: 1 year

Secondary outcomes

  1. Determine if administration of EVs can promote wound healing by serial wound measurements

    Determine if administration of EVs can promote wound healing by serial wound measurements; tissue regeneration as evidenced by restoration of pigmentation and hair growth by serial photography; and skin texture assessment the Patient and Observer Scar Assessment Scale (scale of 1 to 10, where 10 is a worse outcome).

    Time frame: 8 weeks

  2. Laser Doppler will assess differences in dermal perfusion rates between control (unburned) and treated burn tissues.

    Laser Doppler will assess differences in dermal perfusion rates between control (unburned) and treated burn tissues.

    Time frame: 1 year

07

Study locations

2 sites
  • Ryder Trauma Center
    Miami, Florida 33136, United States
  • North Carolina Jaycee Burn Center
    Chapel Hill, North Carolina 27599, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05078385
Lead sponsor
Aegle Therapeutics
Collaborators
Congressionally Directed Medical Research Programs
Responsible party
Sponsor
First posted
Oct 14, 2021
Start date
Aug 10, 2023
Primary completion
Sep 5, 2024
Completion
Nov 19, 2024
Last update
Nov 20, 2024

Study contacts

Carl Schulman, MD
principal investigator · Ryder Trauma Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion